Oncology

MedTech News for Philips, Boston Scientific, Varian

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Philips Teamed with SyntheticMR; BioPhotas’s Celluma Light Therapy; Boston Scientific’s AGENTTM Drug-Coated Balloon; Varian’s TrueBeam and Edge Radiotherapy Systems; Carthera’s Brain-Blood Barrier Trial; Prototype Device Effectively Treated Multiorgan Failure

Philips Teamed with SyntheticMR to Deliver Breakthrough AI-based Quantitative Brain Imaging in MR to Advance Neurology Care For Patients On March 01, 2024, Philips in collaboration with SyntheticMR announced the launch of Smart Quant Neuro 3D, a significant advancement in objective decision support for diagnosing and assessing therapy effectiveness in brain disorders such as Traumatic Brain Injury, Multiple Sclerosis (MS), and Dementia. This innovation aims to assist healthcare providers in delivering high-quality care to patients. The groundbreaking Smart Quant Neuro 3D technology offers automated measurement of diverse brain tissues, improving decision su...

Explore More...

MedTech News and Updates for Vivos, Arthrex, Chindex, Glaukos, Zimmer Biomet

Vivos Therapeutics ‘s DNA Oral Appliance for the Treatment of OSA; Arthrex’s TightRope Implant for Pediatric ACL Surgery; Chindex Medical Acquired 10 ViewRay MRIdian Systems; Zimmer Biomet to Acquire Embody; GE HealthCare to buy IMACTIS; Glaukos Announced the iDose TR Exchange Trial

Latest Pharma News and Updates for Ipsen, Chiesi, Takeda, ACELYRIN, Lantern Pharma

Ipsen to Acquire Albireo; Chiesi Farmaceutici to Buy Amryt Pharma; Takeda Presents Phase III Results of TAK-755 for cTTP; ACELYRIN Acquires ValenzaBio; FDA Approves LEQEMBI for Alzheimer’s Disease; Orphan Drug Designation to Lantern Pharma’s LP-284 for MLL

MedTech News and Updates for Inspira, Burning Rock, Verana, liberDi, Innova

Inspira and Terumo Signed Strategic Agreement; Cook Medical’s New Bipolar Electrodes Portfolio; Verana Health and Sight Sciences Collaborated on Glaucoma Research; Burning Rock’s OverC Multi-Cancer Detection Blood Test; Innova Vascular’s Thrombectomy System; liberDi’s Digital Dialysis System

enhertu-for-cancer-treatment-and-management

ENHERTU’s Journey in Cancer Treatment and Management

Pharma News for Gilead, Roche, AstraZeneca, Genentech, Mirati, Pfizer

Gilead Sciences’ Sunlenca Approval; FDA Approves Roche’s CD20xCD3 Bispecific Antibody Lunsumio; EU Approves AstraZeneca’s Imfinzi Plus Chemo; Pfizer Files Blockbuster Hope Etrasimod for Ulcerative Colitis; FDA Approves Mosunetuzumab for R/F Follicular Lymphoma; FDA Breakthrough Therapy Designation to Adagrasib Plus Cetuximab for KRAS G12C–Mutated Advanced CRC

Awaited Approval for New Therapies for Head and Neck Cancer Treatment – A Race Against Time!

Nuclear Medicine Radiopharmaceuticals Benefit, Applications, Key Companies, and Market Forecast

How is Nuclear Medicine Bringing Groundbreaking Transformation in the Healthcare Industry?

Pharma News and Updates for AbbVie, Ferring, Merck, CSL, Amicus, Takeda

Fourth FDA Approval for AbbVie’s Vraylar; FDA Approves Ferring’s Adstiladrin for NMIBC; Merck and Moderna’s mRNA Cancer Vaccine Trial; EMA Recommends the CSL’s Gene Therapy for Hemophilia B; CHMP Backs Amicus’ Pompe Disease Therapy; Takeda Announces the Phase 3 AURORA Study Result

Bispecific Antibodies in DLBCL, Opportunities and Challenges

Olympus Launches New Gynecologic Power Morcellator; Journey Biosciences Launched NaviDKD; GE Board Approves Separation of GE HealthCare; FDA Approval to Enovis’s STAR Ankle; FDA Clearance to Deep Blue Medical’s T-Line Hernia Mesh; NeuroOne Completed Feasibility Study with its OneRF Ablation System

Pharma News for Nkarta, Eisai, EQRx, Rigel Pharma, AUM, X4 Pharma

Nkarta’s Anti-CD19 Allogeneic CAR-NK Cell Therapy, NKX019; Eisai Presents Results of lecanemab for Alzheimer’s Disease; EQRx’s Aumolertinib for EGFR-Mutated NSCLC; FDA Approves Olutasidenib for IDH1-Mutated R/R AML; FDA Orphan Drug Designation to AUM302 for Neuroblastoma; X4 Pharma Announces Results for WHIM Syndrome Drug

pd-and-pd-l1-inhibitors-in-cancer-treatment

Market & Competitive Assessment

Market Size & Forecast Assessment

Medical Devices

Market Research

Subscription

Competitive Intelligence

Business Consulting

Customized Solutions

Request for Proposal

Blog

Newsletter/Whitepaper

Infographics

Case Study

Events

Press Release

Analysis & Perspective

Oncology

Philips Teamed with SyntheticMR; BioPhotas’s Celluma Light Therapy; Boston Scientific’s AGENTTM Drug-Coated Balloon; Varian’s TrueBeam and Edge Radiotherapy Systems; Carthera’s Brain-Blood Barrier Trial; Prototype Device Effectively Treated Multiorgan Failure

Vivos Therapeutics ‘s DNA Oral Appliance for the Treatment of OSA; Arthrex’s TightRope Implant for Pediatric ACL Surgery; Chindex Medical Acquired 10 ViewRay MRIdian Systems; Zimmer Biomet to Acquire Embody; GE HealthCare to buy IMACTIS; Glaukos Announced the iDose TR Exchange Trial

Ipsen to Acquire Albireo; Chiesi Farmaceutici to Buy Amryt Pharma; Takeda Presents Phase III Results of TAK-755 for cTTP; ACELYRIN Acquires ValenzaBio; FDA Approves LEQEMBI for Alzheimer’s Disease; Orphan Drug Designation to Lantern Pharma’s LP-284 for MLL

Inspira and Terumo Signed Strategic Agreement; Cook Medical’s New Bipolar Electrodes Portfolio; Verana Health and Sight Sciences Collaborated on Glaucoma Research; Burning Rock’s OverC Multi-Cancer Detection Blood Test; Innova Vascular’s Thrombectomy System; liberDi’s Digital Dialysis System

ENHERTU’s Journey in Cancer Treatment and Management

Awaited Approval for New Therapies for Head and Neck Cancer Treatment – A Race Against Time!

How is Nuclear Medicine Bringing Groundbreaking Transformation in the Healthcare Industry?

Fourth FDA Approval for AbbVie’s Vraylar; FDA Approves Ferring’s Adstiladrin for NMIBC; Merck and Moderna’s mRNA Cancer Vaccine Trial; EMA Recommends the CSL’s Gene Therapy for Hemophilia B; CHMP Backs Amicus’ Pompe Disease Therapy; Takeda Announces the Phase 3 AURORA Study Result

More Views & Analysis

ASH 2022- Emergence of Bispecific antibodies in DLBCL: Prospects, Opportunities, and Challenges

ASH 2022: Preview of the Top Abstracts In the Follicular Lymphoma (FL) Therapeutics Market

ASH 2022: Roche’s Polivy vs ADC Therapeutics’ Zynlonta, Antibody-Drug Conjugates (ADC) in R/R DLBCL

ASH 2022: Yescarta emerging as the CAR-T leader in DLBCL; Failure of Kymriah in early lines of DLBCL

ASH 2022 Annual Meeting – Insights Into Major Diffuse Large B-cell Lymphoma (DLBCL) Abstract and Breakthroughs

PD-1 and PD-L1 Inhibitors: Will They Dominate Over Conventional Cancer Therapies?

Subscribe to our Updates

Daily

Weekly

Monthly